Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)

D. Tha├ži*, A. Pinter, M. Sebastian, C. Termeer, M. Sticherling, S. Gerdes, S. Wegner, S. Krampe, H. Bartz, C. Rausch, A. Mensch, K. Eyerich

*Corresponding author for this work
    4 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)'. Together they form a unique fingerprint.

    Medicine & Life Sciences